Sections

Medication

Medication Summary

In December 2016, the US Food and Drug Administration (FDA) approved nusinersen, the first drug approved to treat children (including newborns) and adults with spinal muscular atrophy (SMA). In May 2019, the recombinant AAV9-based gene therapy onasemnogene abeparvovec was approved for SMA type I in children aged 2 years or younger. In August 2020, risdiplam, an SMN2 splicing modifier, was approved for type I, II, and III SMA in adults and children aged 2 months or older.

Class Summary

Antisense oligonucleotides (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency may be considered for treatment.

Nusinersen (Spinraza)

View full drug information

In studies in transgenic animal models of SMA, nusinersen was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein. It is indicated for SMA in pediatric and adults patients.

Class Summary

Recombinant gene therapy provides specificity to precisely treat gene deficiency.

Onasemnogene abeparvovec (Zolgensma)

View full drug information

Recombinant AAV9-based gene therapy designed to deliver a copy of the gene encoding the human survival motor neuron (SMN) protein. It is indicated for gene replacement therapy in children aged 2 years or younger with spinal muscular atrophy (SMA) type 1 (also called Werdnig-Hoffman disease) who have biallelic mutation in the survival motor neuron 1 (SMN1) gene.

Class Summary

Survival of motor neuron 2 (SMN2) mRNA splicing modifiers are designed to treat mutations in chromosome 5q that lead to SMN protein deficiency.

Risdiplam (Evrysdi)

View full drug information

Risdiplam is indicated for spinal muscular atrophy, including types 1, 2, and 3, in adults and children aged 2 months or older.

Questions

Aiona MD, Sarwark JF, Sussman MD. Neuromuscular disorders in children. Orthopaedic Knowledge Update. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1999. 240-241.
Bowen JR, Forlin E. Spinal muscular atrophy. Weinstein SL, ed. The Pediatric Spine: Principles and Practice. New York: Raven Press; 1994. 1025-42.
Cifuentes-Diaz C, Frugier T, Melki J. Spinal muscular atrophy. Semin Pediatr Neurol. 2002 Jun. 9 (2):145-50. [Medline].
Disorders of the spinal cord. Herring JA, ed. Tachdjian's Pediatric Orthopaedics: From the Texas Scottish Rite Hospital for Children. 5th ed. Philadelphia: Elsevier Saunders; 2014. Chap 36.
Werdnig G. Ueber einem Fall von Dystrophiae musculorum mit positivenen Ruckenmakefunde. Wien Med Wochenschr. 1890. 40:1798.
Kugelberg E, Welander L. Heredo-familial juvenile muscular atrophy simulating muscular dystrophy. AMA Arch Neurol Psychiatry. 1956. 75:500.
Hoffman J. Ueber chronische spinale Muskelatophie im Kindersalter. Deutsch Ztschv f Nerrenh. 1891. 1:95.
Soler-Botija C, Ferrer I, Gich I, Baiget M, Tizzano EF. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain. 2002 Jul. 125 (Pt 7):1624-34. [Medline].
Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990 Apr 5. 344 (6266):540-1. [Medline].
Pearn J. Genetic studies of acute infantile spinal muscular atrophy (SMA type I). An analysis of sex ratios, segregation ratios, and sex influence. J Med Genet. 1978 Dec. 15 (6):414-7. [Medline].
Narayanan U, Ospina JK, Frey MR, Hebert MD, Matera AG. SMN, the spinal muscular atrophy protein, forms a pre-import snRNP complex with snurportin1 and importin beta. Hum Mol Genet. 2002 Jul 15. 11 (15):1785-95. [Medline].
Wehner KA, Ayala L, Kim Y, Young PJ, Hosler BA, Lorson CL, et al. Survival motor neuron protein in the nucleolus of mammalian neurons. Brain Res. 2002 Aug 2. 945 (2):160-73. [Medline].
Nguyen thi Man, Humphrey E, Lam LT, Fuller HR, Lynch TA, Sewry CA, et al. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology. 2008 Nov 25. 71 (22):1757-63. [Medline].
Pellizzoni L, Charroux B, Dreyfuss G. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc Natl Acad Sci U S A. 1999 Sep 28. 96 (20):11167-72. [Medline].
Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005 May. 57 (5):704-12. [Medline]. [Full Text].
Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci. 2016. 3:7. [Medline].
Panigrahi I, Kesari A, Phadke SR, Mittal B. Clinical and molecular diagnosis of spinal muscular atrophy. Neurol India. 2002 Jun. 50 (2):117-22. [Medline].
Burd L, Short SK, Martsolf JT, Nelson RA. Prevalence of type I spinal muscular atrophy in North Dakota. Am J Med Genet. 1991 Nov 1. 41 (2):212-5. [Medline].
Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. 2008 Sep. 116 (3):223-34. [Medline].
Thieme A, Mitulla B, Schulze F, Spiegler AW. Epidemiological data on Werdnig-Hoffmann disease in Germany (West-Thüringen). Hum Genet. 1993 Apr. 91 (3):295-7. [Medline].
Hausmanowa-Petrusewicz I, Zaremba J, Borkowska J, Szirkowiec W. Chronic proximal spinal muscular atrophy of childhood and adolescence: sex influence. J Med Genet. 1984 Dec. 21 (6):447-50. [Medline].
Burns JK, Kothary R, Parks RJ. Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy. Neuromuscul Disord. 2016 Sep. 26 (9):551-9. [Medline].
Zeesman S, Whelan DT, Carson N, McGowan-Jordan J, Stockley TL, Ray PN, et al. Parents of children with spinal muscular atrophy are not obligate carriers: carrier testing is important for reproductive decision-making. Am J Med Genet. 2002 Jan 22. 107 (3):247-9. [Medline].
Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008 Sep. 255 (9):1400-4. [Medline].
[Guideline] Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb. 28 (2):103-115. [Medline].
Bouwsma G, Van Wijngaarden GK. Spinal muscular atrophy and hypertrophy of the calves. J Neurol Sci. 1980 Jan. 44 (2-3):275-9. [Medline].
Rudnik-Schöneborn S, Heller R, Berg C, Betzler C, Grimm T, Eggermann T, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet. 2008 Oct. 45 (10):635-8. [Medline].
Lin CW, Kalb SJ, Yeh WS. Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review. Pediatr Neurol. 2015 Oct. 53 (4):293-300. [Medline].
Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol. 2010 Mar. 202 (3):253.e1-7. [Medline].
Pandey R, Chandratre S, Roberts A, Dwyer JS, Sewry C, Quinlivan R. Central core myopathy with RYR1 mutation masks 5q spinal muscular atrophy. Eur J Paediatr Neurol. 2011 Jan. 15 (1):70-3. [Medline].
Weaver MS, Hanna R, Hetzel S, Patterson K, Yuroff A, Sund S, et al. A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions. J Child Neurol. 2020 Apr. 35 (5):322-330. [Medline].
Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: A systematic review. Eur J Paediatr Neurol. 2019 May. 23 (3):347-356. [Medline].
Salazar R, Montes J, Dunaway Young S, et al. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. Pediatr Phys Ther. 2018 Jul. 30 (3):209-215. [Medline].
Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012 Oct 1. 199 (1):21-5. [Medline]. [Full Text].
Haché M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, et al. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. J Child Neurol. 2016 Jun. 31 (7):899-906. [Medline].
Strauss KA, Carson VJ, Brigatti KW, Young M, Robinson DL, Hendrickson C, et al. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy. J Pediatr Orthop. 2018 Nov/Dec. 38 (10):e610-e617. [Medline].
Veerapandiyan A, Pal R, D'Ambrosio S, Young I, Eichinger K, Collins E, et al. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy. Neurology. 2018 Aug 14. 91 (7):e620-e624. [Medline].
Mousa MA, Aria DJ, Schaefer CM, Kaye RD, Abruzzo TA, Bernes SM, et al. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy. Pediatr Radiol. 2018 Nov. 48 (12):1797-1805. [Medline].
Zanetta C, Riboldi G, Nizzardo M, Simone C, Faravelli I, Bresolin N, et al. Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA). J Cell Mol Med. 2014 Feb. 18 (2):187-96. [Medline].
Castro D, Iannaccone ST. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol. 2014 Nov. 16 (11):316. [Medline].
Van Alstyne M, Pellizzoni L. Advances in modeling and treating spinal muscular atrophy. Curr Opin Neurol. 2016 Oct. 29 (5):549-56. [Medline].
Therapeutic approaches. Cure SMA. Available at https://www.curesma.org/therapeutic-approaches/. 2019; Accessed: May 4, 2020.
Spinraza (nusinersen) [package insert]. Cambridge, MA: Biogen Inc. December 2016. Available at [Full Text].
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy - ENDEAR trial. Presented at the British Paediatric Neurology Association (BPNA) Annual Conference in January 2017. Clinical Trials.gov indentifier: NCT02193074.
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy – CHERISH trial. Clinical Trials.gov identifier: NCT02292537.
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020 Jan 6. 1:CD006282. [Medline].
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2019 Dec 11. 12:CD006281. [Medline].
Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020 Apr. 19 (4):317-325. [Medline].
[Guideline] Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Nov 13. 91 (20):923-933. [Medline].
Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb. 54 (2):179-185. [Medline]. [Full Text].
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2. 377 (18):1713-1722. [Medline]. [Full Text].
Servais L, Baranello G, Masson R, et al. FIREFISH Part 2: efficacy and safety of risdiplam (RG7916) in infants with spinal muscular atrophy (SMA) (1302). Neurology. April 14, 2020;94 (15 suppl). Presented at the 72nd Annual meeting of the American Academy of Neurology, April 25-May 1, 2020. [Full Text].
Evrysdi (risdiplam) [package insert]. South San Francisco, CA: Genentech. August 2020. Available at [Full Text].
Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L. Spinal muscular atrophy disease: a literature review for therapeutic strategies. J Med Life. 2010 Jan-Mar. 3 (1):3-9. [Medline].
Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet. 2010 Apr 15. 19:R111-8. [Medline]. [Full Text].
Han JJ, McDonald CM. Diagnosis and clinical management of spinal muscular atrophy. Phys Med Rehabil Clin N Am. 2008 Aug. 19 (3):661-80, xii. [Medline].
Sauvagnac-Quera R, Vabre C, Azzi V, Tirolien S, Leiba N, Poisson F, et al. Prevention and treatment of scoliosis by Garches Brace in children with type Ib SMA. Ann Phys Rehabil Med. 2016 Sep. 59S:e92. [Medline].
Fujak A, Raab W, Schuh A, Kreß A, Forst R, Forst J. Operative treatment of scoliosis in proximal spinal muscular atrophy: results of 41 patients. Arch Orthop Trauma Surg. 2012 Dec. 132 (12):1697-706. [Medline].
Wijngaarde CA, Brink RC, de Kort FAS, Stam M, Otto LAM, Asselman FL, et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology. 2019 Jul 9. 93 (2):e149-e158. [Medline].
McElroy MJ, Shaner AC, Crawford TO, Thompson GH, Kadakia RV, Akbarnia BA, et al. Growing rods for scoliosis in spinal muscular atrophy: structural effects, complications, and hospital stays. Spine (Phila Pa 1976). 2011 Jul 15. 36 (16):1305-11. [Medline].
Chandran S, McCarthy J, Noonan K, Mann D, Nemeth B, Guiliani T. Early treatment of scoliosis with growing rods in children with severe spinal muscular atrophy: a preliminary report. J Pediatr Orthop. 2011 Jun. 31 (4):450-4. [Medline].
Campbell RM Jr. VEPTR: past experience and the future of VEPTR principles. Eur Spine J. 2013 Mar. 22 Suppl 2:S106-17. [Medline]. [Full Text].
Chua K, Tan CY, Chen Z, Wong HK, Lee EH, Tay SK, et al. Long-term Follow-up of Pulmonary Function and Scoliosis in Patients With Duchenne's Muscular Dystrophy and Spinal Muscular Atrophy. J Pediatr Orthop. 2016 Jan. 36 (1):63-9. [Medline].
Holt JB, Dolan LA, Weinstein SL. Outcomes of Primary Posterior Spinal Fusion for Scoliosis in Spinal Muscular Atrophy: Clinical, Radiographic, and Pulmonary Outcomes and Complications. J Pediatr Orthop. 2017 Dec. 37 (8):e505-e511. [Medline].
Lenhart RL, Youlo S, Schroth MK, Noonan KJ, McCarthy J, Mann D, et al. Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy. J Pediatr Orthop. 2017 Dec. 37 (8):e500-e504. [Medline]. [Full Text].
Hell AK, Braunschweig L, Tsaknakis K, von Deimling U, Lüders KA, Hecker M, et al. Children With Spinal Muscular Atrophy With Prior Growth-Friendly Spinal Implants Have Better Results After Definite Spinal Fusion in Comparison to Untreated Patients. Neurosurgery. 2020 Mar 14. [Medline].
Hanna R, Sharafinski M, Patterson K, Noonan KJ, Sund S, Schultz M, et al. Is prophylactic formal fusion with implant revision necessary in non-ambulatory children with spinal muscular atrophy and growing rods who are no longer lengthened?. Spine Deform. 2020 Feb 24. [Medline].
Fujak A, Kopschina C, Gras F, Forst R, Forst J. Contractures of the lower extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection. Ortop Traumatol Rehabil. 2011 Jan-Feb. 13 (1):27-36. [Medline].
Wang HY, Ju YH, Chen SM, Lo SK, Jong YJ. Joint range of motion limitations in children and young adults with spinal muscular atrophy. Arch Phys Med Rehabil. 2004 Oct. 85 (10):1689-93. [Medline].
Shanmugarajan S, Swoboda KJ, Iannaccone ST, Ries WL, Maria BL, Reddy SV. Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol. 2007 Aug. 22 (8):967-73. [Medline]. [Full Text].
Fujak A, Kopschina C, Forst R, Gras F, Mueller LA, Forst J. Fractures in proximal spinal muscular atrophy. Arch Orthop Trauma Surg. 2010 Jun. 130 (6):775-80. [Medline].
Narver HL, Kong L, Burnett BG, Choe DW, Bosch-Marcé M, Taye AA, et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol. 2008 Oct. 64 (4):465-70. [Medline].
Mehta NM, Newman H, Tarrant S, Graham RJ. Nutritional Status and Nutrient Intake Challenges in Children With Spinal Muscular Atrophy. Pediatr Neurol. 2016 Apr. 57:80-3. [Medline].
Takeuchi Y, Katsuno M, Banno H, Suzuki K, Kawashima M, Atsuta N, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. 2008 Aug. 38 (2):964-71. [Medline].
Aagaard P, Suetta C, Caserotti P, Magnusson SP, Kjaer M. Role of the nervous system in sarcopenia and muscle atrophy with aging: strength training as a countermeasure. Scand J Med Sci Sports. 2010 Feb. 20 (1):49-64. [Medline].
[Guideline] Finkel RS, Mercuri E, Meyer OH, Simonds AK, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar. 28 (3):197-207. [Medline].
Schwentker EP, Gibson DA. The orthopaedic aspects of spinal muscular atrophy. J Bone Joint Surg Am. 1976 Jan. 58 (1):32-8. [Medline].
Shapiro F, Specht L. The diagnosis and orthopaedic treatment of childhood spinal muscular atrophy, peripheral neuropathy, Friedreich ataxia, and arthrogryposis. J Bone Joint Surg Am. 1993 Nov. 75 (11):1699-714. [Medline].

Media Gallery

Spinal muscle atrophy, Werdnig-Hoffman disease. Small muscle fibers within separate muscle fascicles.
Spinal muscle atrophy, Werdnig-Hoffman disease. Marked variation in muscle fiber size, as well as relative increase in associated connective tissue.
Spinal muscle atrophy, Kugelberg-Welander disease. Marked variation in muscle fiber size, along with increased perimysial connective tissue.
Spinal muscle atrophy, Kugelberg-Welander disease. Muscle-fiber variation with some demonstrating internal nuclei.
Spinal muscle atrophy. At age 4 years, this boy's chest radiograph already reveals presence of significant 32° left thoracic scoliosis. Diagnosis is type I spinal muscle atrophy (Werdnig-Hoffmann disease). This radiograph captures the lumbar curvature incompletely.
Spinal muscle atrophy. By age 6 years, child's curve is starting to decompensate. Note development of right-side truncal shift. He now has 40° thoracic curve and 60° lumbar curve.
Spinal muscle atrophy. Spine anteroposterior view. Spinal curvature is progressing. Lumbar curve now is 70°, and thoracic curve is 35°. It is now clearly apparent that right hip is dislocated. Also note marked pelvic obliquity in this patient.
Spinal muscle atrophy. By age 9 years, this patient with type I spinal muscle atrophy now has thoracic curve of 60° and lumbar curve of 110°. Note that patient has tracheostomy tube and nasogastric tube as well.
Spinal muscle atrophy. Immediate postoperative anteroposterior radiograph of patient at age 9 years. Thoracic curve is now at 18°, and lumbar curve is 35°, which represents more than 67% curvature correction.
Spinal muscle atrophy. Immediate postoperative lateral view with good sagittal balance.
Spinal muscle atrophy. Follow-up radiographs in patient at age 13 years reveal some spinal decompensation. Note so-called coathanger appearance of ribs in dysplastic right hemithorax.
Spinal muscle atrophy. Anteroposterior radiograph of pelvis demonstrating right hip dislocation.
Spinal muscle atrophy. Lauenstein lateral view of hips on patient with spinal muscle atrophy type I. Note near-universal pelvic dysmorphology (eg, widened obturator foramina) in addition to dislocated right hip.

of 13

Author

Ashish S Ranade, MBBS, MS, MRCS Consultant Orthopaedic Surgeon, Columbia Asia Hospital and Deenanath Mangeshkar Hospital, India

Ashish S Ranade, MBBS, MS, MRCS is a member of the following medical societies: Paediatric Orthopaedic Society of India

Disclosure: Nothing to disclose.

Coauthor(s)

Mohan V Belthur, MD, FRCSC, FRCS(Tr&Orth) Clinical Assistant Professor, Departments of Child Health, Orthopedics, and Pediatrics, University of Arizona College of Medicine; Staff Pediatric Orthopedic Surgeon, Center for Pediatric Orthopedics, Phoenix Children’s Hospital

Mohan V Belthur, MD, FRCSC, FRCS(Tr&Orth) is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Orthopaedic Surgeons, American College of Surgeons, AO Trauma, Limb Lengthening and Reconstruction Society, Paediatric Orthopaedic Society of India, Pediatric Orthopaedic Society of North America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jeffrey A Goldstein, MD Clinical Professor of Orthopedic Surgery, New York University School of Medicine; Director of Spine Service, Director of Spine Fellowship, Department of Orthopedic Surgery, NYU Hospital for Joint Diseases, NYU Langone Medical Center

Jeffrey A Goldstein, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American College of Surgeons, American Orthopaedic Association, AOSpine, Cervical Spine Research Society, International Society for the Advancement of Spine Surgery, International Society for the Study of the Lumbar Spine, Lumbar Spine Research Society, North American Spine Society, Scoliosis Research Society, Society of Lateral Access Surgery

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Medtronic, Nuvasive, NLT Spine, RTI, Magellan Health<br/>Received consulting fee from Medtronic for consulting; Received consulting fee from NuVasive for consulting; Received royalty from Nuvasive for consulting; Received consulting fee from K2M for consulting; Received ownership interest from NuVasive for none.

Additional Contributors

James F Kellam, MD, FRCSC, FACS, FRCS(Ire) Professor, Department of Orthopedic Surgery, University of Texas Medical School at Houston

James F Kellam, MD, FRCSC, FACS, FRCS(Ire) is a member of the following medical societies: American Academy of Orthopaedic Surgeons, Orthopaedic Trauma Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Charles T Mehlman, DO, MPH Professor of Pediatrics and Pediatric Orthopedic Surgery, Division of Pediatric Orthopedic Surgery, Director, Musculoskeletal Outcomes Research, Cincinnati Children's Hospital Medical Center

Charles T Mehlman, DO, MPH is a member of the following medical societies: American Academy of Pediatrics, American Fracture Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America, American Medical Association, American Orthopaedic Foot and Ankle Society, American Osteopathic Association, Arthroscopy Association of North America, North American Spine Society, Ohio State Medical Association

Disclosure: Nothing to disclose.

Alvin H Crawford, MD, FACS Professor Emeritus of Pediatrics and Orthopedic Surgery, University of Cincinnati College of Medicine; Director, Founding Division of Pediatric Orthopedic Surgery, Department of Orthopedic Surgery, Cincinnati Children's Hospital Medical Center

Alvin H Crawford, MD, FACS is a member of the following medical societies: Ohio State Medical Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America

Disclosure: Nothing to disclose.

Jose A Herrera-Soto, MD Director of Orthopedic Research, Associate Director of Pediatric Orthopedic Surgery Fellowship Program, Arnold Palmer Hospital for Children, International Hip Dysplasia Institute, Orlando Health

Jose A Herrera-Soto, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, North American Spine Society, Pediatric Orthopaedic Society of North America, Scoliosis Research Society

Disclosure: Nothing to disclose.

Spinal Muscle Atrophy Medication

Medication Summary

Antisense Oligonucleotides

Class Summary

Nusinersen (Spinraza)

Nusinersen (Spinraza)

Gene Therapy

Class Summary

Onasemnogene abeparvovec (Zolgensma)

Onasemnogene abeparvovec (Zolgensma)

SMN Splicing Modifiers

Class Summary

Risdiplam (Evrysdi)

Risdiplam (Evrysdi)

Spinal Muscle Atrophy Medication

Medication Summary

Antisense Oligonucleotides

Class Summary

Nusinersen (Spinraza)

Nusinersen (Spinraza)

Gene Therapy

Class Summary

Onasemnogene abeparvovec (Zolgensma)

Onasemnogene abeparvovec (Zolgensma)

SMN Splicing Modifiers

Class Summary

Risdiplam (Evrysdi)

Risdiplam (Evrysdi)

References

Tables

Contributor Information and Disclosures

What would you like to print?